{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:38:09Z","timestamp":1792521489137,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:00:00Z","timestamp":1763769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The immune response and safety using different COVID-19 vaccine platforms in patients with immune mediated rheumatic diseases is still uncertain. The objective of this study is to compare the immunogenicity and safety after two doses of BNT162b2, CoronaVac and ChadOx-1 in SLE patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Prospective study including SLE patients who received a primary schedule to COVID-19 vaccination between May and August 2021. Immunogenicity, events supposedly attributable to vaccination or immunization (ESAVI) and disease activity were assessed at baseline and after each vaccine dose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>121 SLE patients were included in the cohort, 88 in the immunogenicity analysis and 118 in the safety analysis. The groups were homogenous concerning sex, age, and comorbidities. Seropositivity after two doses of vaccines was similar between CoronaVac (68%), ChadOx1 (80,6%) and BNT162b2 (88%) (p=0.231). However, CoronaVac and ChadOx-1 presented lower titers in comparison with BNT162b2.\u00a0 Regarding ESAVI, the most frequent reported following first and second vaccine doses were, respectively: injection site pain (65.2%\/41.1%), headache (50.9%\/29.9%) and arthralgia (37.5%\/22.5%). Fever and myalgia were more related to ChAdOx1 than CoronaVac (23.3 vs. 5.0%; p=0.025). There was no difference in MEX-SLEDAI between vaccine platforms. No serious ESAVI were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>After two doses, the three COVID-19 vaccine platforms induced a significant increase in antibody titers against SARS-CoV-2. Patients who received BNT162b2 exhibited a higher serological response compared to the other vaccines. All three vaccine platforms demonstrated a favorable safety profile, with no serious ESAVI or worsening of disease activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial Number<\/jats:title>\n                    <jats:p>The study was registered in The Brazilian Registry of Clinical Trials (ReBEC) in 04\/14\/2021 with code RBR-108fyykd.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s42358-025-00498-9","type":"journal-article","created":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T09:54:08Z","timestamp":1763805248000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of the immunogenicity and safety among COVID-19 vaccines ChadOx-1, CoronaVac and BNT162b2 in systemic lupus erythematosus (SLE) patients: a prospective cohort"],"prefix":"10.1186","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2598-810X","authenticated-orcid":false,"given":"Priscila Dias Cardoso","family":"Ribeiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia Maria Matos Melo Campos","family":"Peixoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0657-4825","authenticated-orcid":false,"given":"Edgard Torres dos","family":"Reis-Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0054-7754","authenticated-orcid":false,"given":"Gecilmara Salviato","family":"Pileggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6080-5693","authenticated-orcid":false,"given":"Nancy Cristina Junqueira","family":"Bellei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1896-8322","authenticated-orcid":false,"given":"Marcelo de Medeiros","family":"Pinheiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8662-4786","authenticated-orcid":false,"given":"Vanessa de Oliveira","family":"Magalh\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4978-040X","authenticated-orcid":false,"given":"Erika","family":"Biegelmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8874-7736","authenticated-orcid":false,"given":"Andr\u00e9 Gustavo Cunha","family":"Trolese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7681-6215","authenticated-orcid":false,"given":"Alexandre Wagner","family":"Silva de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0543-5305","authenticated-orcid":false,"given":"Cristiane","family":"Kayser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0625-1308","authenticated-orcid":false,"given":"Val\u00e9ria","family":"Valim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2545-6795","authenticated-orcid":false,"given":"Ketty Lysie Libardi Lira","family":"Machado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maressa Barbosa Beloni","family":"Lirio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana Ribeiro","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2814-5183","authenticated-orcid":false,"given":"Andrea Teixeira","family":"de Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1623-259X","authenticated-orcid":false,"given":"Rodrigo Poubel","family":"Vieira de Rezende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4809-9965","authenticated-orcid":false,"given":"Ana Karla","family":"Guedes de Melo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4475-6064","authenticated-orcid":false,"given":"Rejane Maria Rodrigues de Abreu","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3073-2929","authenticated-orcid":false,"given":"Vitor Alve","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6386-3776","authenticated-orcid":false,"given":"Viviane","family":"Angelina de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1352-7261","authenticated-orcid":false,"given":"Gilda Aparecida","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4777-8659","authenticated-orcid":false,"given":"Sandra L\u00facia Euz\u00e9bio","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0720-2097","authenticated-orcid":false,"given":"Odirlei","family":"Monticielo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6570-4533","authenticated-orcid":false,"given":"Ricardo Machado","family":"Xavier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4316-0771","authenticated-orcid":false,"given":"Natalia Sarzi","family":"Sartori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8540-014X","authenticated-orcid":false,"given":"Emilia Inoue","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,22]]},"reference":[{"issue":"17","key":"498_CR1","doi-asserted-by":"publisher","first-page":"e794","DOI":"10.1097\/MD.0000000000000794","volume":"94","author":"Z Wang","year":"2015","unstructured":"Wang Z, et al. Long-term survival and death causes of systemic lupus erythematosus in China: a systemic review of observational studies. Med (Baltim). 2015;94(17):e794.","journal-title":"Med (baltim)"},{"issue":"5","key":"498_CR2","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/00005792-198709000-00002","volume":"66","author":"DB Hellmann","year":"1987","unstructured":"Hellmann DB, Petri M, Whiting-O\u2019Keefe Q. Fatal infections in systemic lupus erythematosus: the role of opportunistic organisms. Med (Baltim). 1987;66(5):341\u201348.","journal-title":"Med (Baltim)"},{"issue":"1","key":"498_CR3","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1093\/rheumatology\/keaa478","volume":"60","author":"JM Pego-Reigosa","year":"2021","unstructured":"Pego-Reigosa JM, et al. The risk of infections in adult patients with systemic lupus erythematosus: systematic review and meta-analysis. Rheumatol (oxford). 2021;60(1):60\u201372.","journal-title":"Rheumatol (oxford)"},{"issue":"12","key":"498_CR4","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1136\/ard.60.12.1141","volume":"60","author":"V No\u00ebl","year":"2001","unstructured":"No\u00ebl V, et al. Risk factors and prognostic influence of infection in a single cohort of 87 adults with systemic lupus erythematosus. Ann Rheum Dis. 2001;60(12):1141\u201344.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"498_CR5","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s12916-016-0673-8","volume":"14","author":"JA Singh","year":"2016","unstructured":"Singh JA, et al. Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis. BMC Med. 2016;14(1):137.","journal-title":"BMC Med"},{"issue":"8","key":"498_CR6","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1177\/0961203308101019","volume":"18","author":"F Goldblatt","year":"2009","unstructured":"Goldblatt F, et al. Serious infections in British patients with systemic lupus erythematosus: hospitalisations and mortality. Lupus. 2009;18(8):682\u201389.","journal-title":"Lupus"},{"issue":"6","key":"498_CR7","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1007\/BF01451283","volume":"17","author":"S Jacobsen","year":"1998","unstructured":"Jacobsen S, et al. A multicentre study of 513 Danish patients with systemic lupus erythematosus. ii. Disease mortality and clinical factors of prognostic value. Clin Rheumatol. 1998;17(6):478\u201384.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"498_CR8","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.semarthrit.2017.01.010","volume":"47","author":"\u00cd R\u00faa-Figueroa","year":"2017","unstructured":"R\u00faa-Figueroa \u00cd, et al. Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus. Semin Arthritis Rheum. 2017;47(1):38\u201345.","journal-title":"Semin Arthritis Rheum"},{"key":"498_CR9","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.3389\/fimmu.2018.03144","volume":"9","author":"J Torres-Ruiz","year":"2018","unstructured":"Torres-Ruiz J, et al. The systemic lupus erythematosus infection predictive index (LIPI): a clinical-immunological tool to predict infections in lupus patients. Front Immunol. 2018;9:3144.","journal-title":"Front Immunol"},{"key":"498_CR10","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3389\/fimmu.2016.00055","volume":"7","author":"AC Macedo","year":"2016","unstructured":"Macedo AC, Isaac L. Systemic lupus erythematosus and deficiencies of early components of the complement classical pathway. Front Immunol. 2016;7:55.","journal-title":"Front Immunol"},{"issue":"4","key":"498_CR11","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1128\/CMR.00048-09","volume":"23","author":"S Ram","year":"2010","unstructured":"Ram S, Lewis LA, Rice PA. Infections of people with complement deficiencies and patients who have undergone splenectomy. Clin Microbiol Rev. 2010;23(4):740\u201380.","journal-title":"Clin Microbiol Rev"},{"issue":"2","key":"498_CR12","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s10875-015-0137-5","volume":"35","author":"AJ Turley","year":"2015","unstructured":"Turley AJ, et al. Spectrum and management of complement immunodeficiencies (excluding hereditary angioedema) across Europe. J Clin Immunol. 2015;35(2):199\u2013205.","journal-title":"J Clin Immunol"},{"issue":"5","key":"498_CR13","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S0049-0172(96)80018-7","volume":"25","author":"AG Iliopoulos","year":"1996","unstructured":"Iliopoulos AG, Tsokos GC. Immunopathogenesis and spectrum of infections in systemic lupus erythematosus. Semin Arthritis Rheum. 1996;25(5):318\u201336.","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"498_CR14","doi-asserted-by":"publisher","first-page":"e028697","DOI":"10.1136\/bmjopen-2018-028697","volume":"9","author":"B Tejera Segura","year":"2019","unstructured":"Tejera Segura B, et al. Can we validate a clinical score to predict the risk of severe infection in patients with systemic lupus erythematosus? A longitudinal retrospective study in a British Cohort. BMJ Open. 2019;9(6):e028697.","journal-title":"BMJ Open"},{"issue":"5","key":"498_CR15","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.2215\/CJN.01290308","volume":"3","author":"LS Dalrymple","year":"2008","unstructured":"Dalrymple LS, Go AS. Epidemiology of acute infections among patients with chronic kidney disease. Clin J Am Soc Nephrol. 2008;3(5):1487\u201393.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"498_CR16","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1136\/annrheumdis-2020-217871","volume":"79","author":"M Gianfrancesco","year":"2020","unstructured":"Gianfrancesco M, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79(7):859\u201366.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"498_CR17","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1136\/annrheumdis-2020-219498","volume":"80","author":"A Strangfeld","year":"2021","unstructured":"Strangfeld A, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021;80(7):930\u201342.","journal-title":"Ann Rheum Dis"},{"key":"498_CR18","unstructured":"Organization, W.o.H.. Who health emergencies programme. 2024. https:\/\/data.who.int\/dashboards\/covid19\/deaths?n=c."},{"issue":"27","key":"498_CR19","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med. 2020;383(27):2603\u201315.","journal-title":"N Engl J Med"},{"issue":"5","key":"498_CR20","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden LR, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403\u201316.","journal-title":"N Engl J Med"},{"issue":"10269","key":"498_CR21","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey M, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99\u2013111.","journal-title":"Lancet"},{"issue":"10296","key":"498_CR22","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0140-6736(21)01429-X","volume":"398","author":"MD Tanriover","year":"2021","unstructured":"Tanriover MD, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021;398(10296):213\u201322.","journal-title":"Lancet"},{"issue":"23","key":"498_CR23","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","volume":"384","author":"J Sadoff","year":"2021","unstructured":"Sadoff J, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021;384(23):2187\u2013201.","journal-title":"N Engl J Med"},{"key":"498_CR24","doi-asserted-by":"crossref","unstructured":"Zimmermann P, Curtis N. Factors that influence the immune response to vaccination. Clin Microbiol Rev. 2019;32(2).","DOI":"10.1128\/CMR.00084-18"},{"issue":"10223","key":"498_CR25","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497\u2013506.","journal-title":"Lancet"},{"issue":"10","key":"498_CR26","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1136\/annrheumdis-2021-220647","volume":"80","author":"V Furer","year":"2021","unstructured":"Furer V, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis. 2021;80(10):1330\u201338.","journal-title":"Ann Rheum Dis"},{"key":"498_CR27","doi-asserted-by":"crossref","unstructured":"Deepak P, et al. Glucocorticoids and B cell depleting agents substantially impair immunogenicity of mRNA vaccines to SARS-CoV-2. medRxiv, 2021.","DOI":"10.1101\/2021.04.05.21254656"},{"issue":"9","key":"498_CR28","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/acr2.11299","volume":"3","author":"C Ammitzb\u00f8ll","year":"2021","unstructured":"Ammitzb\u00f8ll C, et al. Impaired antibody response to the BNT162b2 Messenger rna coronavirus disease 2019 vaccine in patients with systemic lupus erythematosus and rheumatoid arthritis. ACR Open Rheumatol. 2021;3(9):622\u201328.","journal-title":"ACR Open Rheumatol"},{"issue":"10","key":"498_CR29","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1136\/annrheumdis-2021-220656","volume":"80","author":"JA Ruddy","year":"2021","unstructured":"Ruddy JA, et al. High antibody response to two-dose SARS-CoV-2 messenger rna vaccination in patients with rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2021;80(10):1351\u201352.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"498_CR30","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1038\/s41591-021-01469-5","volume":"27","author":"AC Medeiros-Ribeiro","year":"2021","unstructured":"Medeiros-Ribeiro AC, et al. Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial. Nat Med. 2021;27(10):1744\u201351.","journal-title":"Nat Med"},{"key":"498_CR31","doi-asserted-by":"publisher","first-page":"1759720X2210895","DOI":"10.1177\/1759720X221089586","volume":"14","author":"H So","year":"2022","unstructured":"So H, et al. Immunogenicity and safety of inactivated and mRNA COVID-19 vaccines in patients with systemic lupus erythematosus. Ther Adv Musculoskelet Dis. 2022;14:1759720X221089586.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"4","key":"498_CR32","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/acr.24824","volume":"74","author":"EFN Yuki","year":"2022","unstructured":"Yuki EFN, et al. Impact of distinct therapies on antibody response to SARS-CoV-2 vaccine in systemic lupus erythematosus. Arthritis Care Res (hoboken). 2022;74(4):562\u201371.","journal-title":"Arthritis Care Res (hoboken)"},{"issue":"10","key":"498_CR33","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1136\/annrheumdis-2021-220597","volume":"80","author":"RH Haberman","year":"2021","unstructured":"Haberman RH, et al. Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. Ann Rheum Dis. 2021;80(10):1339\u201344.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"498_CR34","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s42358-019-0056-x","volume":"59","author":"GS Pileggi","year":"2019","unstructured":"Pileggi GS, et al. Brazilian recommendations on the safety and effectiveness of the yellow fever vaccination in patients with chronic immune-mediated inflammatory diseases. Adv Rheumatol. 2019;59(1):17.","journal-title":"Adv Rheumatol"},{"issue":"10","key":"498_CR35","first-page":"1551","volume":"19","author":"J Guzm\u00e1n","year":"1992","unstructured":"Guzm\u00e1n J, et al. Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices. J Rheumatol. 1992;19(10):1551\u201358.","journal-title":"J Rheumatol"},{"issue":"2","key":"498_CR36","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/art.41937","volume":"74","author":"PM Izmirly","year":"2022","unstructured":"Izmirly PM, et al. Evaluation of immune response and disease status in systemic lupus erythematosus patients following SARS-CoV-2 vaccination. Arthritis Rheumatol. 2022;74(2):284\u201394.","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"498_CR37","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1093\/infdis\/jiab593","volume":"225","author":"V Naranbhai","year":"2022","unstructured":"Naranbhai V, et al. Comparative immunogenicity and effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 vaccines. The J Infect Dis. 2022;225(7):1141\u201350.","journal-title":"The J Infect Dis"},{"key":"498_CR38","doi-asserted-by":"crossref","unstructured":"Sarker P, et al. Comparison of the immune responses to COVID-19 vaccines in Bangladeshi population. Vaccines (Basel). 2022;10(9).","DOI":"10.3390\/vaccines10091498"},{"issue":"3","key":"498_CR39","doi-asserted-by":"publisher","first-page":"e439","DOI":"10.1093\/cid\/ciac392","volume":"76","author":"NJ Epsi","year":"2023","unstructured":"Epsi NJ, et al. Understanding \u201cHybrid Immunity\u201d: comparison and predictors of humoral immune responses to severe acute respiratory syndrome coronavirus 2 infection (SARS-CoV-2) and coronavirus disease 2019 (COVID-19) vaccines. Clin Infect Dis. 2023;76(3):e439\u201349.","journal-title":"Clin Infect Dis"},{"key":"498_CR40","doi-asserted-by":"publisher","first-page":"103972","DOI":"10.1016\/j.ebiom.2022.103972","volume":"78","author":"NA Muena","year":"2022","unstructured":"Muena NA, et al. Induction of SARS-CoV-2 neutralizing antibodies by CoronaVac and BNT162b2 vaccines in na\u00efve and previously infected individuals. EBioMedicine. 2022;78:103972.","journal-title":"EBioMedicine"},{"key":"498_CR41","doi-asserted-by":"crossref","unstructured":"Tien N, et al. The immunogenicity and safety of three types of SARS-CoV-2 vaccines in adult patients with immune-mediated inflammatory diseases: a longitudinal cohort study. Biomedicines. 2022;10(4).","DOI":"10.3390\/biomedicines10040911"},{"key":"498_CR42","doi-asserted-by":"crossref","unstructured":"Assawasaksakul T, et al. Comparison of immunogenicity and safety of inactivated, adenovirus-vectored, and heterologous adenovirus-vectored\/mRNA vaccines in patients with systemic lupus erythematosus and rheumatoid arthritis: a prospective cohort study. Vaccines (Basel). 2022;10(6).","DOI":"10.3390\/vaccines10060853"},{"issue":"6","key":"498_CR43","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1136\/annrheumdis-2021-221922","volume":"81","author":"S Ahmed","year":"2022","unstructured":"Ahmed S, et al. Postvaccination antibody titres predict protection against COVID-19 in patients with autoimmune diseases: survival analysis in a prospective cohort. Ann Rheum Dis. 2022;81(6):868\u201374.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"498_CR44","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","volume":"27","author":"S Feng","year":"2021","unstructured":"Feng S, et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med. 2021;27(11):2032\u201340.","journal-title":"Nat Med"},{"issue":"10267","key":"498_CR45","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","volume":"396","author":"MN Ramasamy","year":"2021","unstructured":"Ramasamy MN, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial. Lancet. 2021;396(10267):1979\u201393.","journal-title":"Lancet"},{"key":"498_CR46","doi-asserted-by":"crossref","unstructured":"Gerosa M, et al. The impact of anti-SARS-CoV-2 vaccine in patients with systemic lupus erythematosus: a multicentre cohort study. Vaccines (Basel). 2022;10(5).","DOI":"10.3390\/vaccines10050663"},{"issue":"9","key":"498_CR47","doi-asserted-by":"publisher","first-page":"e613","DOI":"10.1016\/S2665-9913(21)00221-6","volume":"3","author":"R Felten","year":"2021","unstructured":"Felten R, et al. Tolerance of COVID-19 vaccination in patients with systemic lupus erythematosus: the international VACOLUP study. Lancet Rheumatol. 2021;3(9):e613\u201315.","journal-title":"Lancet Rheumatol"},{"issue":"11","key":"498_CR48","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s00296-021-04972-7","volume":"41","author":"LE Bartels","year":"2021","unstructured":"Bartels LE, et al. Local and systemic reactogenicity of COVID-19 vaccine BNT162b2 in patients with systemic lupus erythematosus and rheumatoid arthritis. Rheumatol Int. 2021;41(11):1925\u201331.","journal-title":"Rheumatol Int"},{"issue":"8","key":"498_CR49","doi-asserted-by":"publisher","first-page":"e542","DOI":"10.1016\/S2665-9913(21)00181-8","volume":"3","author":"L Boekel","year":"2021","unstructured":"Boekel L, et al. Adverse events after first COVID-19 vaccination in patients with autoimmune diseases. Lancet Rheumatol. 2021;3(8):e542\u201345.","journal-title":"Lancet Rheumatol"},{"issue":"2","key":"498_CR50","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s10238-022-00832-1","volume":"23","author":"Q Tang","year":"2023","unstructured":"Tang Q, et al. Attitudes towards and safety of the SARS-CoV-2 inactivated vaccines in 188 patients with systemic lupus erythematosus: a post-vaccination cross-sectional survey. Clin Exp Med. 2023;23(2):457\u201363.","journal-title":"Clin Exp Med"},{"issue":"5","key":"498_CR51","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1007\/s10067-021-05980-5","volume":"41","author":"E Zavala-Flores","year":"2022","unstructured":"Zavala-Flores E, et al. Side effects and flares risk after SARS-CoV-2 vaccination in patients with systemic lupus erythematosus. Clin Rheumatol. 2022;41(5):1349\u201357.","journal-title":"Clin Rheumatol"},{"issue":"5","key":"498_CR52","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1007\/s10067-021-05963-6","volume":"41","author":"M Barbhaiya","year":"2022","unstructured":"Barbhaiya M, et al. Adverse events and disease flares after SARS-CoV-2 vaccination in patients with systemic lupus erythematosus. Clin Rheumatol. 2022;41(5):1619\u201322.","journal-title":"Clin Rheumatol"},{"key":"498_CR53","first-page":"100153","volume":"10","author":"N Angkasekwinai","year":"2022","unstructured":"Angkasekwinai N, et al. Comparison of safety and immunogenicity of CoronaVac and ChAdOx1 against the SARS-CoV-2 circulating variants of concern (Alpha, Delta, Beta) in Thai healthcare workers. Vaccine. 2022;10:100153.","journal-title":"Vaccine"},{"issue":"12","key":"498_CR54","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1016\/S1473-3099(22)00502-3","volume":"22","author":"R Lazarus","year":"2022","unstructured":"Lazarus R, et al. Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial. Lancet Infect Dis. 2022;22(12):1716\u201327.","journal-title":"Lancet Infect Dis"},{"issue":"10324","key":"498_CR55","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0140-6736(22)00094-0","volume":"399","author":"SA Costa Clemens","year":"2022","unstructured":"Costa Clemens SA, Weckx L, Clemens R, et al. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Lancet. 2022, Feb, 5;399(10324):521\u201329.","journal-title":"Lancet"},{"key":"498_CR56","doi-asserted-by":"publisher","first-page":"714170","DOI":"10.3389\/fimmu.2021.714170","volume":"12","author":"N Sharif","year":"2021","unstructured":"Sharif N, Alzahrani KJ, Ahmed SN, Dey SK. Efficacy, immunogenicity and safety of COVID-19 vaccines: a systematic review and meta-analysis. Front Immunol. 2021;12:714170. https:\/\/doi.org\/10.3389\/fimmu.2021.714170.","journal-title":"Front Immunol"},{"key":"498_CR57","doi-asserted-by":"crossref","unstructured":"Yoshida T, et al. Medium-term impact of the SARS-CoV-2 mRNA vaccine against disease activity in patients with systemic lupus erythematosus. Lupus Sci Med. 2022;9(1).","DOI":"10.1136\/lupus-2022-000727"}],"container-title":["Advances in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-025-00498-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42358-025-00498-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-025-00498-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T20:02:07Z","timestamp":1767038527000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s42358-025-00498-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,22]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["498"],"URL":"https:\/\/doi.org\/10.1186\/s42358-025-00498-9","relation":{},"ISSN":["2523-3106"],"issn-type":[{"value":"2523-3106","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,22]]},"assertion":[{"value":"26 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from each participant. The study was conducted in accordance with the Declaration of Helsinki and was reviewed and approved by the coordinating center\u2019s ethics committee (Research Ethics Committee of the Universidade Federal de S\u00e3o Paulo, CAAE: 43479221.0.1001.5505).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"67"}}